AnaptysBio (ANAB) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

ANAB · Stock Price

USD 66.96+47.37 (+241.81%)

Market Cap: $2.0B

Historical price data

Market Cap: $2.0BPipeline: 8 drugsPatents: 20Founded: 2005HQ: San Diego, United States

Overview

AnaptysBio is a San Diego-based clinical-stage biotech focused on developing innovative antibody therapeutics for autoimmune and inflammatory diseases. The company operates a dual-strategy model, advancing a proprietary clinical pipeline while generating revenue from royalties on out-licensed assets like the PD-1 antagonist Jemperli. Its transformational plan to separate into two independent public companies by end of 2026 aims to provide investors with distinct investment theses: high-growth biopharma and stable royalty income.

Autoimmune DiseasesInflammatory Diseases

Technology Platform

Proprietary antibody discovery and engineering platform focused on generating best-in-class, fully human monoclonal antibodies to modulate immune cell function and restore immune balance.

Pipeline

8

8 drugs in pipeline

Drug	Indication	Stage
Rosnilimab + Placebo	Ulcerative Colitis	Phase 2
Rosnilimab + Placebo	Rheumatoid Arthritis	Phase 2
Etokimab + Placebo + Mometasone Furoate Nasal Spray	Chronic Rhinosinusitis	Phase 2
Rosnilimab + Placebo	Alopecia Areata	Phase 2
ANB032 + Placebo	Atopic Dermatitis Eczema	Phase 2

Opportunities

The strategic separation unlocks value by allowing pure-play investment in a high-growth clinical pipeline (ANB033, rosnilimab) and a stable royalty company.

Large, underserved markets in celiac disease and EoE present multi-billion dollar opportunities for a first/best-in-class therapy.

Risk Factors

High clinical development risk across all Phase 1/2b assets.

Execution risk associated with the complex corporate separation.

Future funding needs for the clinical-stage entity post-spin remain a consideration.

Competitive Landscape

Faces intense competition in all target indications from large pharma and other biotechs. Differentiation will require demonstrating superior efficacy/safety in crowded markets like rheumatoid arthritis and eosinophilic esophagitis.

More companies in United States →